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Pathogens that evade adaptive immunity typically
exhibit antigenic variation. By contrast, it appears
that although the chronic human tuberculosis
(TB)-causing pathogen Mycobacterium tuberculosis
needs to counter host T cell responses, its T cell
epitopes are hyperconserved. Here we present
an extensive analysis of the T cell epitopes of
M. tuberculosis. We combined population genomics
with experimental immunology to determine the
number and identity of T cell epitope sequence vari-
ants in 216 phylogenetically diverse strains of
M. tuberculosis. Antigen conservation is indeed a
hallmark of M. tuberculosis. However, our analysis
revealed a set of seven variable antigens that were
immunogenic in subjects with active TB. These
findings suggest that M. tuberculosis uses mecha-
nisms other than antigenic variation to evade
T cells. T cell epitopes that exhibit sequence variation
may not be subject to the same evasion mecha-
nisms, and hence vaccines that include such variable
epitopes may be more efficacious.
INTRODUCTION
Microbial pathogens must adapt to host environments to estab-
lish replicative niches and counter innate and adaptive immune
responses. The need to adapt is especially marked for obligate
pathogens that must infect, replicate, and be transmitted to
new hosts to survive and propagate. In the case of pathogens
that encounter adaptive immune responses, a common mecha-
nism of adaptation is antigenic variation, in which pathogen tar-
gets that are recognized by antibodies and T lymphocytes
develop escape mutations that allow them to evade recognition
and elimination by the host immune system (Deitsch et al., 2009;538 Cell Host & Microbe 18, 538–548, November 11, 2015 ª2015 ElsGoulder et al., 2001; Heaton et al., 2013; Palmer et al., 2009). As
pathogens evolve to evade host immunity by antigenic variation,
hosts respond by developing antibodies and T cells with speci-
ficity to the newly selected antigens. The cycle of antigenic vari-
ation and host response can be continuous (Dawkins and Krebs,
1979; Woolhouse et al., 2002). The consequences of antigenic
variation can include persistent viral (Dustin and Rice, 2007),
parasitic, or bacterial infection (Deitsch et al., 2009; Palmer
et al., 2009), pandemics of diseases such as influenza (Itoh
et al., 2009), and reinfection after recovery (Henderson et al.,
1979). Antigenic variation also impacts vaccine development,
by compelling the use of multivalent vaccines (containing multi-
ple antigenic variants) such as for poliovirus and Streptococcus
pneumoniae, or by requiring new vaccines at regular intervals,
such as for influenza. Extreme antigenic variation confounds
development of HIV vaccines that can protect against diverse
viral strains (Walker and Korber, 2001).
Mycobacterium tuberculosis and other members of the
Mycobacterium tuberculosis complex (MTBC) cause tubercu-
losis (TB) (Coscolla and Gagneux, 2014), a chronic infection
transmitted by the aerosol route that remains a major global
health problem despite the availability of drug treatment (WHO,
2014). M. tuberculosis is an obligate human pathogen, as it has
no ecological niche other than its human hosts, with which it
has coevolved for thousands of years (Bos et al., 2014; Comas
et al., 2013). The success of M. tuberculosis as a pathogen is
due to its efficiency of transmission and its ability to evade
elimination by adaptive immune responses (Ernst, 2012). Immu-
nity to M. tuberculosis depends on T lymphocytes, as T cell-
deficient humans, nonhuman primates, andmice are susceptible
to rapidly progressive disease (Kwan and Ernst, 2011; Lin et al.,
2009; North and Jung, 2004). Among T lymphocytes, CD4 T cells
are essential for protective immunity to TB: in HIV-infected
humans, loss of CD4 T cells greatly increases susceptibility to
TB, and reconstitution of CD4 T cells by antiretroviral therapy
reduces susceptibility to TB (Kwan and Ernst, 2011). Humans
also generate CD8 T cell responses to M. tuberculosis antigens
during infection, but the contribution of CD8 T cells to protection
is less clear (Lancioni et al., 2012). Despite development of CD4evier Inc.
and CD8 T cell responses directed against M. tuberculosis anti-
gens, the bacteria can persist for the life of an individual, allowing
for reactivation, progression, and transmission of TB. The mech-
anisms that allow persistence and progression ofM. tuberculosis
infection are incompletely understood, but they include modula-
tion of bacterial antigen expression, inefficient antigen presenta-
tion, and bacterial interference with T cell effector mechanisms
(Ernst, 2012). The contribution of antigenic variation to immune
evasion in TB is also incompletely understood.
For T cells to contribute to immunity, they must recognize spe-
cific peptides (termed epitope peptides), generated by proteoly-
sis of pathogen proteins, bound tomajor histocompatibility com-
plex (MHC) molecules on the surface of antigen presenting cells.
CD4 T cells recognize epitope peptides bound to MHC (human
leukocyte antigen [HLA] in humans) class II molecules, while
CD8 T cells recognize peptides bound toMHC/HLA class Iamol-
ecules. For a given epitope to be immunogenic, it must bind with
sufficient affinity to one or more MHC proteins, and the peptide-
MHC complex must be recognized by a clonotypic T cell antigen
receptor. Variation in the sequence of an epitope can result in
loss of MHC binding and recognition by T cells (Corradin and
Chiller, 1979), indicating that sequence variation of pathogen
molecules can result in escape from control of infection by
T cells (Farci et al., 2000; Kawashima et al., 2009).
To determine whether antigenic (epitope peptide) sequence
variation contributes to immune evasion in human TB, we previ-
ously characterized the sequences of 491 human T cell epitopes
in the genomes of 21 phylogenetically diverse strains of the
MTBC and unexpectedly found that the T cell epitopes of the
MTBC are hyperconserved (Comas et al., 2010). In that study,
95% of the T cell epitopes studied contained no amino acid sub-
stitutions, even in bacterial strains that diverged from a common
ancestor thousands of years ago. This observation implied that
human T cell recognition of the known human T cell epitopes
ofM. tuberculosis is not sufficiently detrimental to the pathogen
to select for escape variants. If the persistence and evolutionary
success of M. tuberculosis do not involve antigenic variation, it
will be necessary to formulate new models for understanding
the biology of TB and certain other infectious diseases, espe-
cially those that have been refractory to development of effica-
cious vaccines.
Although the results of our previous study established that
T cell epitopes are hyperconserved, M. tuberculosis clearly
adapts to antimicrobial drug pressure by development of
resistance through chromosomal mutations, and not through
horizontal gene exchange (Borrell and Gagneux, 2011;
Goldberg et al., 2012; Mu¨ller et al., 2013). This indicates that
M. tuberculosis can respond to selection pressure with adaptive
mutations, and the finding of a very low frequency of epitope
variation in our previous study may have been influenced by
the approach commonly employed to discover T cell epitopes.
Indeed, most studies to date have used derivatives (native or
recombinant antigens, or synthetic peptides) based on the
M. tuberculosis reference strain H37Rv, a member of the
MTBC Lineage 4 (Gagneux and Small, 2007). Use of those deriv-
atives to identify epitopes recognized by T cells of individuals
who were infected by strains from MTBC lineages other than
Lineage 4 may bias the results toward discovery of conserved
epitopes. In addition, since the total number of antigens andCell Host &T cell epitopes encoded by the MTBC genome is unknown, it
is possible that there are epitopes that have not been identified
with usual approaches and that are under diversifying selection
from T cell recognition.
To better understand the evolutionary impact of human T cell
recognition, and to determine the extent of M. tuberculosis anti-
genic variation, we first extended our analysis to an expanded
set of experimentally validated epitopes and a larger number of
bacterial strains. We then analyzed the genomes of 216 strains
representative of the seven main human-adapted phylogenetic
lineages of the MTBC (Coscolla and Gagneux, 2014) and used
an innovative strategy based on a combination of population
genomics and computational and experimental immunology to
determine the number and the identity of human T cell epitopes
with naturally occurring sequence variants. Our findings reinforce
the finding of epitope conservation, reveal a small number of epi-
topeswithsequencevariants, and indicate that antigenicvariation
is not a major mechanism of immune evasion inM. tuberculosis.
RESULTS
Expanded Analysis of Epitopes and Bacterial Strains
Confirms Conservation of Human T Cell Epitopes in
M. tuberculosis
Our initial finding of hyperconservation of the epitopes of
M. tuberculosis recognized by human T cells was based on the
analysis of 21 genomes and 491 T cell epitopes; this may have
limited the likelihood of finding epitopes with sequence variants.
To better define the frequency of conserved and of variable
epitopes, we analyzed the genomes of 216 bacterial strains
(Comas et al., 2013) representative of the seven known
human-adapted phylogenetic lineages of the MTBC (Coscolla
and Gagneux, 2014). Recent epitope discovery efforts also facil-
itated our analysis of conservation and diversity of a larger num-
ber of human T cell epitopes.
We first identified 1,730 epitopes cataloged in the Immune
Epitope Database (http://www.iedb.org). After excluding epi-
topes in repetitive regions (see Supplemental Experimental Pro-
cedures), we used 1,226 of these for analysis of their sequence
diversity in the 216 phylogenetically diverse bacterial strains (Co-
mas et al., 2013). This revealed that 953 (78%) of the 1,226 epi-
topes contained no amino acid variants in the 216 strains, while
we found one amino acid substitution in 232 (19%) of the epi-
topes (Figure 1A). Notably, of the epitopes in which we found
one amino acid substitution, 57% were found in a single isolate.
No epitope exhibited more than three distinct amino acid vari-
ants. To further explore the degree of T cell epitope conserva-
tion, we compared the ratios of non-synonymous to synony-
mous substitution rates (dN/dS) in epitopes and other
elements of the MTBC genome (Figure 1B). Consistent with
our previous observation (Comas et al., 2010), we found that
essential genes showed a significantly lower dN/dS than nones-
sential genes (Wilcoxon signed-rank test p = 5.615). This was
expected, as essential genes are known to be under stronger
purifying selection than nonessential genes. Again consistent
with our previous findings (Comas et al., 2010), we found that
all epitope regions combined showed a significantly lower
dN/dS compared to the corresponding nonepitope regions of
the same proteins, or to essential genes (Wilcoxon signed-rankMicrobe 18, 538–548, November 11, 2015 ª2015 Elsevier Inc. 539
Figure 1. Genetic Diversity of Experimentally Verified Human T Cell
Epitopes of M. tuberculosis
(A) Frequency distribution of the number of epitopes (total n = 1,226) with the
stated number of sequence variants.
(B) Comparison of dN/dS of epitopes considered in (A); nonepitope domains of
the epitope-containing proteins; essential proteins, and nonessential proteins
of M. tuberculosis.test p = p < 2.216 and p = 4.414, respectively) (Figure 1B). Since
inclusion of epitopes in the IEDB does not require that peptides
meet preset criteria (Ernst et al., 2008), we separately analyzed a
subset of 163 peptides (included in the initial set of 1,226) iden-
tified in a recent T cell epitope screen as the most immunodomi-
nant among 20,610 peptides examined (Lindestam Arlehamn
et al., 2013). After filtering out epitopes found in repetitive loci
(58/163), we found that 9 of the 105 immunodominant epitopes
(8.6%) contained sequence variants in more than one strain,
while 11 additional epitopes contain variants in a single strain
(singletons) (Table S1). Since singletons may be transient and
destined to be removed by purifying selection, their biological
significance is uncertain. Thus, expanded analyses of a larger
number of epitopes in a larger number of bacterial strains
confirmed that sequence conservation dominates in the known
T cell epitopes of M. tuberculosis.540 Cell Host & Microbe 18, 538–548, November 11, 2015 ª2015 ElsSince the present experimental approaches toM. tuberculosis
epitope discovery may be biased toward discovery of conserved
epitopes (by studying responses to antigens or epitope peptides
derived from bacteria from a single phylogenetic lineage), we
used an alternative approach to determine the existence and
frequency of human T cell epitopes with sequence variants in
the MTBC. We reasoned that effective immune recognition
would drive a higher level of sequence diversity than the genome
average in genes that encode antigens containing variable epi-
topes and that variable epitopes could be discovered by use of
comparative genomics.
Identification of Variable Regions in theM. tuberculosis
Genome
To identifyandquantitatevariablecandidateantigens in theMTBC
genome, we analyzed 3,774 coding regions in whole genome
sequences of 216 human-adapted MTBC strains representative
of the seven main lineages (Comas et al., 2013) (Figure 2). First,
we calculated the nucleotide diversity (p), defined as the average
number of nucleotide differences per site between any two
DNA sequences chosen randomly. This revealed a median
p = 0.0002 for all coding regions, ranging from 0 to 0.0046,
compared to p = 0.0003 for the whole genome (Figure 2,
Table S2). Because only nSNPs lead to amino acid changes and
potential antigenic variation, we further focused our analyses on
coding regions exhibiting high rates of nSNPs. To this end, we
selected the most variable 5% of the genes (N = 189; Table S2)
and determined that the dN/dS in these genes ranged from 0 to
4.21; 47% (88/189) of the genes showed a dN/dS > 1 (Table S2).
Because 19 genes showed only nSNPs, a dN/dS value could not
be calculated for these genes and was indicated as ‘‘infinite’’ (Ta-
ble S2).
Next, we selected genes for further characterization based on
the three following criteria: (1) ranking in the 5% of genes with
the highestp (Table S2), (2) a dN/dS> 1, and (3) harboring at least
one nSNP present in an entire MTBC lineage (Table S2). To
assess the possibility that the impact of a given nSNP on immune
response depends on its distribution in the MTBC phylogeny, we
also selected candidates with variants in distinct lineages. A total
of seven genes were chosen for further analyses. These seven
genes were associated with several functional categories (Lew
et al., 2011), including cell wall and cell processes (3 genes), inter-
mediary metabolism (2 genes), lipid metabolism (1 gene), and
information pathways (1 gene) (Table S3). The protein products
encoded by 5 of the 7 genes have been detected in proteomics
studies that have revealed the presence of 3 of them in the bacte-
rial membrane fraction (de Souza et al., 2011;Mawuenyega et al.,
2005;Rosenkrandsetal., 2000;Schubertet al., 2013).Noneof the
proteins were predicted or determined to be secreted.
Epitope Prediction
To explore whether sequence diversity in the seven genes of
interest could be related to human T cell recognition, we first
computationally predicted human CD4 and CD8 T cell epitopes
in the protein products of these genes using HLA class I and HLA
class II alleles that are prevalent in diverse human populations
(Hoof et al., 2009; Nielsen et al., 2010) (Table S4). This identified
amean of 207 potential high-affinity epitopes per protein for HLA
class I and 150 epitopes per protein for HLA class II.evier Inc.
Figure 2. Visualization of M. tuberculosis Genetic Diversity on a Circular Map of the Chromosome of the H37Rv Reference Strain
The first ring from the outside shows the scale of the chromosome in nucleotides. The spikes in the second ring (red) illustrate the seven highly variable genes
identified in the present study. The third ring (blue) denotes genes encoding previously reported T cell epitopes (Vita et al., 2010). The spikes radiating from the
innermost circle represent a histogram of the mean pairwise nucleotide diversity (p) per gene shown in Table S2, ranging from 0 to 0.002. Average p for the whole
genome is indicated by the green circle. Surrounding the circular map, insets show the genomic regions containing the selected genes in this work highlighted in
yellow, and the p values of these genes are shown in the accompanying bar graphs. See also Table S2.We then examined the relationship between the predicted
human T cell epitopes and DNA sequence variation in the seven
genes of interest. Comparative analysis of the 216 whole
genomes revealed 56 nSNPs in these seven genes (Table S5).
Moreover, we found that 91% (51/56) of these nSNPs coincided
with predicted CD4 and/or CD8 T cell epitopes (Figure 3). We
then evaluated whether the corresponding amino acid changes
altered the results of the epitope predictions. We found that on
average, a given amino acid substitution led to 5% fewer
predicted CD4 T cell epitopes (range, 0%–8%) and 18% fewer
predicted CD8 T cell epitopes, ranging from 11% (10 of 88 for
RimJ) to 53% (9 of 17 for TB7.3) (Table S6A). To test whether
this reduction in the number of predicted CD4 and CD8 epitopesCell Host &encoded by these genes was statistically significant, we
selected a control set of 100 predicted T cell epitopes from
random regions of the MTBC genome that contained nSNPs
(Table S6B) and evaluated the consequences of these nSNPs
on the predicted binding affinity of this other set of epitopes.
We found that the impact of nSNPs on predicted CD4 T cell
epitopes was similar regardless of whether the epitopes were
derived from the seven genes of interest or elsewhere in the
genome. In contrast, for the predicted CD8 T cell epitopes,
nSNPs in the seven genes of interest were 5 times more likely
to affect the predicted epitope binding than nSNPs in predicted
epitopes encoded in the random proteins (16% versus 3.3%;
c2 = 8.233, p < 0.005). These results suggest that the sevenMicrobe 18, 538–548, November 11, 2015 ª2015 Elsevier Inc. 541
Figure 3. Location of 82 Naturally Occurring
Amino Acid Substitutions and Predicted
CD4 and CD8 T Cell Epitopes in Seven
Candidate M. tuberculosis Antigens
For each protein, a length scale in amino acids is
shown. The red rectangles highlight regions con-
taining predicted CD4 and/or CD8 T cell epitopes
for which predicted HLA binding affinity was
affected by amino acid substitutions. The number
of affected predicted T cell epitopes per protein is
indicated in the white boxes. T cell epitope pre-
dictions were done using HLA molecules repre-
senting major global human populations (Table S4
and accompanying map).genes of interest identified here are under distinct selection pres-
sures compared with random genes in the MTBC genome, and
that this difference could be due to CD8 T cell recognition.
Next, we examined the impact of naturally occurring sequence
variation on the predicted capacity of putative epitope peptides
to bind to selectedHLA alleles with high affinity.We found that on
average, a nSNP decreased the binding affinity of 25% (7 of 33)
and 18% (9 of 51) of the predicted peptide:HLA class I and
peptide:HLA class II interactions, respectively (Table S6A). We
also found that the naturally occurring sequence variation could
lead to an increase in the number of HLA alleles capable of high-
affinity binding of the corresponding epitope peptide. Overall,
epitope variants were predicted to form 4–13 new HLA class
I and 2–17 new HLA class II high-affinity binding interactions
(Table S6A). In summary, our results indicate that the naturally
occurring sequence variation in epitopes predicted from our
seven genes of interest can result in either loss or gain of recog-
nition by human T cells.
The different phylogenetic lineages of the MTBC have been
associated with different human populations (Brites and Gag-
neux, 2015), and some MTBC lineages are more globally wide-
spread than others (Coscolla and Gagneux, 2014). Because 53
of the 56 (95%) nSNPs found in the seven genes of interest
were specific to individual MTBC lineages, we assessed the
possibility that the impact of a given nSNP on T cell epitope
recognition depends on its distribution in the MTBC phylogeny
and the corresponding human population. We initially concen-
trated on nSNPs specific to Lineage 4 (also known as the
Euro-American lineage), because it is the most successful
MTBC lineage worldwide and also well represented in our strain542 Cell Host & Microbe 18, 538–548, November 11, 2015 ª2015 Elsevier Inc.collection. Moreover, HLA allele fre-
quencies are best characterized in the
Caucasian populations where Lineage 4
strains are prevalent. This analysis
revealed that the 14 nSNPs specific to
Lineage 4 strains led to a net decrease
of 17% of the predicted T cell epitopes
(Table S6C). By contrast, we found that
nSNPs in Lineages 1, 3, or 6 increase
the number of predicted epitopes by an
average of 37% (Table S6C). The latter
finding may be related to the relative
lack of success of Lineage 1, 3, and 6compared to Lineage 4 in spreading globally (Hershberg
et al., 2008).
Immunogenicity of Peptides Representing Candidate
Variable CD4 and CD8 T Cell Epitopes
To experimentally validate our epitope predictions, we assessed
the immunogenicity of the predicted T cell epitopes and their
respective naturally occurring sequence variants by assaying
immune responses from 88 sputum smear-positive, HIV-sero-
negative adults with newly diagnosed TB in The Gambia. For
this analysis, we focused on variable T cell epitopes with high
affinities for the HLA alleles that are most prevalent in The
Gambia (Table S4). A total of nine CD4 and five CD8 candidate
T cell epitopes were selected, containing 16 amino acid changes
predicted to alter the interactions with some or all selected HLA
alleles (Figure 4). In total, 30 peptides corresponding to 14 ances-
tral (present in the MTBC common ancestor) and 16 variant (any
departure from the ancestral) sequences were synthesized from
the seven genes of interest (Figure 4). Each peptide was used to
stimulate fresh diluted whole blood samples followed by ELISA
quantitation of interferon gamma (IFN-g) in supernatants. Cells
of six of the subjects did not respond to any of three positive con-
trols; therefore the IFN-g responses of 82 subjects were used for
further analysis (Table S7).
Each of the candidate epitope peptides was immunogenic
in subjects with active TB, as defined by the ability to stimulate
IFN-g release to a level at least 2-fold higher than the individual
subject’s unstimulated control sample. When considered
together, the ancestral and variant sequences of each peptide
induced responses from the cells of an average of 12 subjects
Figure 4. Localizationof thePeptidesRepre-
senting Candidate Variable CD4 and CD8
T Cell Epitopes Predicted Using HLA Mole-
cules Prevalent in the Gambian Population
For each protein, a length scale in amino acids is
shown. The rectangles depict the positions of the
candidate CD4 (yellow) and CD8 (blue) T cell
epitopes within the protein sequences. Each
epitope is also represented by an arrow and
associated with a candidate epitope number (from
CE1 to CE14). The amino acid sequences in black
are the sequences of the candidate epitopes in
the inferred most recent common ancestor of the
MTBC. The sequences in white font represent the
naturally occurring variants identified in this work;
the amino acid changes compared with the
ancestral sequence are in bold. Each variant
sequence is color-coded according to its distri-
bution in the MTBC phylogeny. The phylogenetic
lineages and the number of strains containing the
variant version of each epitope sequence are also
indicated. See also Tables S2, S3, and S5.(Figure 5A, Table S7). By summing the responses to all peptides
from one protein, we found that epitopes in RimJ and Rv0010c
induced responses in R 30% of the subjects (Figure 5B).
Considered separately, the HLA class I and class II candidate
epitopes stimulated the cells of an average of 12% and 16% of
subjects (10/82 and 13/82), respectively. No statistically signifi-
cant difference was found between these percentages, indi-
cating that the accuracy of predicting immunogenic HLA class
I and class II epitopes did not differ.
Fifty-two of the 82 (63%) subjects with TB responded to at least
one candidate epitope peptide. Cells from individual subjects
responded to an average of 3 of the 30 (10%) candidate epitope
peptides (ancestral and/or variant form), although cells of some
subjects responded to as many as 22 (73.3%). The amount of
IFN-g secreted in response to peptide stimulation of cells from
certain subjects was in a range similar to that observed when a
pool of overlapping peptides from ESAT-6 and CFP10 was used,
indicating that the candidate epitope peptideswere immunogenic
in this population (Figure 6A). Of note, epitope peptides from
Rv0010c stimulated responses from the highest fraction of the
subjects, and also induced responses with the highest magnitude
(Figure 6A). Evidence that responses to the peptideswere attribut-
able to infection withM. tuberculosis was obtained by analysis of
responses obtained after 2 months and 6 months of drug treat-
ment for TB. With the exception of Candidate Epitope 3 (CE3;
fromRv2719c), the magnitude of the responses decreased signif-
icantly with successful treatment and resolution of TB (Figure 6B).Cell Host & Microbe 18, 538–548, NTo assess the impact of the amino
acid substitutions on the responses to
the candidate epitope peptides, we
compared the responses (assayed as
IFN-g secretion) induced by the ancestral
or the variant sequences of each of the
14 candidate epitopes. We found that an
average of 72% of the responding
subjects for a given candidate epitope
exhibited differential responses to theancestral compared with the variant sequences of each of the
14 candidate epitopes (designated CE1–CE14) (Tables S7
and S8). Amino acid substitutions in 10 of the 14 candidate
epitopes altered T cell responses in themajority of the responding
subjects (ranging from 63% of the responding subjects for CE14
to 87% for CE3, Bayesian p < 0.05) (Tables S7 and S8, Figures
7A and 7B). Amino acid substitutions in the four other candidate
epitopes influenced T cell responses in a smaller fraction of the
subjects, although all of them still altered the responses in
> 40% of the subjects (Table S7). Notably, amino acid changes
in CE9 completely abrogated T cell responses in eight individuals
(Figure 7A). CE12, contained in RimJ, was distinct from the other
candidate epitopes, as more of the subjects responded to the
variantpeptides than to theancestral peptide (Figure7B).Whether
this reflects a difference in the sequence of this epitope in the bac-
terial strains infecting these subjects, or a difference in binding of
thevariant peptides to thesubjects’HLAalleles,will require further
investigation. Together, our results demonstrate that naturally
occurring sequence variation in these candidate T cell epitopes
affects host recognition, suggesting that T cell recognition is a fac-
tor driving variation in the seven genes identified in this study.
DISCUSSION
The most significant findings of the present study are the strong
evidence that antigen and epitope conservation dominate in
M. tuberculosis, and the discovery of human T cell epitopesovember 11, 2015 ª2015 Elsevier Inc. 543
Figure 5. Frequency of Immune Responses to the Candidate T Cell
Epitopes Selected in This Work
(A and B) The results were derived from the diluted whole blood assay using
cells from 82 human subjects with active TB, stimulated with synthetic epitope
peptides, followed by quantitation of secreted IFN-g. Number of subjects
(of 82 total) responding to (A) the ancestral or variant sequences of each
candidate epitope or (B) to all peptides derived from each antigenic protein.
Responses were defined as a stimulation index > 2, as defined in Experimental
Procedures. Each bar represents the cumulative responses to the ancestral
and variant sequences of each candidate epitope. See also Table S7.that exhibit sequence variation and evidence of diversifying
selective pressure. The combination of two distinct approaches
to determining the frequency of conserved and variable T cell
epitopes in the genome of M. tuberculosis yielded incontrovert-
ible evidence that epitope sequence conservation is the rule, and
not the exception, in this highly successful human pathogen.
First, we examined 1,226 experimentally verified peptide
epitopes for sequence variants in 216 phylogenetically diverse
strains of the MTBC and confirmed that the vast majority
(78%) showed no amino acid variation. Moreover, we confirmed
that T cell epitopes in the MTBC are significantly more evolution-
arily conserved than non-epitope regions in the same antigens.
Second, we used a comparative genomics strategy, which
avoids the potential discovery bias of the former approach to
determine the frequency and identity of human T cell epitopes
with sequence variants and confirmed their recognition by cells
of humans with pulmonary TB. This effort revealed a small num-
ber of variable epitopes, indicating that, even though epitope
sequence conservation dominates in M. tuberculosis, there are
exceptions, and these had not been identified by standard
approaches. Together, the results reveal that M. tuberculosis544 Cell Host & Microbe 18, 538–548, November 11, 2015 ª2015 Elsemploys epitope sequence variation only rarely as an evolu-
tionary strategy to evade recognition by human T cells. Since
epitope peptides are the sole molecular interface of the path-
ogen with T cells, and since T cells are the most important
component of protective adaptive immunity in TB, our results
indicate that these bacteria have evolved to use mechanisms
other than antigenic variation to evade T cell immunity.
The findings we report here are consistent with the conclu-
sions of our recent analysis of the pe_pgrs gene family in
M. tuberculosis that had been proposed to be involved in anti-
genic variation (Cole et al., 1998). That analysis of 27 pe_pgrs
genes in 94 phylogenetically diverse strains of M. tuberculosis
revealed that, although certain of the pe_pgrs genes are highly
polymorphic, their sequence polymorphisms and indels are
concentrated in the C-terminal PGRS domains, while their
T cell epitopes are concentrated in the conserved N-terminal
PE domain (Copin et al., 2014). Therefore, in the products of
the pe_pgrs genes, despite their high frequency of sequence
and structural variants, the T cell epitopes are conserved.
The evidence that M. tuberculosis does not employ antigenic
variation as a major mechanism of adaptation and immune
evasion is unexpected, since M. tuberculosis causes chronic
infection that can persist for the life of the host. This indicates
that the bacteria are highly successful in using other mecha-
nisms to evade elimination by adaptive immune responses.
Since other pathogens that cause chronic infections, including
HIV (Liu et al., 2013), hepatitis C virus (Farci, 2011), Trypanosoma
cruzei (Mugnier et al., 2015), and Treponema pallidum (Reid
et al., 2014), employ antigenic variation to cause persistent infec-
tion, M. tuberculosis stands as a prominent exception to an
increasingly widely accepted rule.
The unexpected finding of antigen and epitope conservation in
M. tuberculosis compels consideration of an explanation for the
results. One potential explanation is that during coevolution with
humans, M. tuberculosis has derived a net evolutionary benefit
from T cell recognition, despite the within-host cost that T cell
responses impose on the bacteria in the majority of infected in-
dividuals. As noted previously, one possible mechanism of an
evolutionary benefit to the bacteria in the context of epitope con-
servation is through the inflammatory lung tissue damage char-
acteristic of human cavitary tuberculosis, whose incidence is
directly related to the number of circulating CD4 T cells at the
time of TB diagnosis in HIV-coinfected individuals (Kwan and
Ernst, 2011) and which is associated with high transmission of
infection (Reichler et al., 2002). A second potential explanation
for the dominance of conserved epitopes in M. tuberculosis is
that the epitopes are derived from domains of proteins that serve
an essential function for the bacteria and are therefore con-
strained in their inherent mutational tolerance. Although this is
a plausible explanation, 76% of the epitopes we analyzed here
are encoded by nonessential genes, and our efforts to date
have not detected evidence that human T cell epitopes in
M. tuberculosis have common structural motifs or that they are
preferentially derived from active sites in proteins with known
enzymatic functions (R.C. and J.D.E., unpublished data). How-
ever, in support of this latter model is the recent observation
that certain of the known T cell epitopes of M. tuberculosis are
also conserved in nonpathogenic mycobacteria, which are not
under selection pressure in a mammalian host (Lindestamevier Inc.
Figure 6. Quantitation of IFN-g from Diluted
Whole Blood Samples Stimulated with
Synthetic Peptides Representing Ancestral
Sequences of the Candidate Epitopes
(A) Each diamond represents the response of a
single subject; the horizontal blue line represents
the median response calculated using data
from responders only. The vertical line represents
the interquartile range. Each value is the net
concentration after subtraction of background
determined with an unstimulated sample from
each subject assayed simultaneously (see also
Table S7).
(B) Comparison of responses (as IFN-g release in
pg/ml) after 2 and 6 months of TB treatment,
compared with responses before treatment.
Results were obtained by subtracting response
values measured after 2 months (blue circles) or
6 months (red triangle) of treatment from those
before treatment in the same subject. Statistical
analysis was done by Wilcoxon signed-rank test;
*p < 0.05, **p < 0.01, or ***p < 0.001; blue asterisks
represent analysis of differences after 2 months,
and red asterisks represent analysis of differences
after 6 months of treatment.Arlehamn et al., 2015). Similarly, T cell epitopes are also
conserved in Mycobacterium canettii, which is a member of
theMTBC that otherwise showsmuch genomic diversity (Supply
et al., 2013).
In addition to being unexpected, the finding that antigenic vari-
ation is the exception rather than the rule in M. tuberculosis has
implications for understanding the immunopathogenesis of TB. If
antigenic variation does not contribute to the persistence of
M. tuberculosis in immunocompetent individuals with measur-
able T cell responses, then other potent mechanisms for evading
elimination of the bacteria by immune responses must accountCell Host & Microbe 18, 538–548, Nfor bacterial persistence and chronic
infection. SinceM. tuberculosis occupies
professional antigen-presenting cells
such as dendritic cells and macrophages
(Ernst, 2012; Philips and Ernst, 2012), it
is not surprising that there is evidence
for the bacteria manipulating antigen
presentation to T cells. For example,
multiple studies provide evidence that
M. tuberculosis interferes with MHC class
II antigen presentation to CD4 T cells
(reviewed in Baena and Porcelli, 2009),
and M. tuberculosis inhibits apoptosis in
diverse subsets of antigen-presenting
cells in vivo (Blomgran et al., 2012; Vel-
murugan et al., 2007), which decreases
cross-presentation to CD8 T cells (Divan-
gahi et al., 2010). These and other
mechanisms may allow the bacteria to
survive and cause progressive disease
and transmission of infection without
requiring antigenic variation as a mecha-
nism of immune evasion.Apart from the importance for understanding TB pathogen-
esis, the significance of antigen and epitope conservation should
be considered in developing TB vaccines directed at inducing
T cell responses. If bacterial persistence and survival in TB is pre-
dominantly accomplished by manipulating infected antigen-pre-
senting cells to minimize their recognition by antigen-specific
CD4 or CD8 T cells, then these mechanisms may also limit the
efficacy of vaccine-induced T cells. The modest impact of exist-
ing (e.g., BCG) and experimental TB vaccines to date (Andersen
and Woodworth, 2014) suggests that there are potent mecha-
nisms that restrict the efficacy of antigen-specific T cells at theovember 11, 2015 ª2015 Elsevier Inc. 545
Figure 7. Naturally Occurring Amino Acid
Variants Alter Immune Recognition of
Candidate Epitopes
(A and B) Comparison of the magnitude of IFN-g
secretion from cells of individual subjects induced
by the ancestral and the variant sequences of
individual candidate epitopes.
(A) Responses of individuals whose cells
responded to the ancestral but not the variant
sequence peptide.
(B) Responses of individuals whose cells
responded to the variant but not the ancestral
sequence of each candidate. Each connecting
line represents responses of a single subject.
Responses were defined as a stimulation index
> 2, as defined in Experimental Procedures. See
also Table S8.site of infection; our results that human T cell recognition
does not impose a measurable selection pressure on
M. tuberculosis to evade these responses are consistent with
this possibility. The finding of T cell epitopes that exhibit
sequence variation implies that these epitopes are not subject
to the same evasion mechanisms employed by those in the
hyperconserved immunodominant antigens of M. tuberculosis.
This suggests that vaccines that include such variable epitopes
may be more efficacious than those containing conserved,
immunodominant epitopes. In this sense, our search for variable
epitopes under diversifying selection can be considered to be a
variation of ‘‘reverse vaccinology’’ (Sette and Rappuoli, 2010).
Finally, our finding thatM. tuberculosis does not adhere to the
canonical model of a host-pathogen arms race should prompt
reconsideration of the generalizability of that model. Although it546 Cell Host & Microbe 18, 538–548, November 11, 2015 ª2015 Elsevier Inc.is clear that antigenic variation is
employed by diverse, highly successful
pathogens, our results indicate that in
other pathogens, especially those with
unique and narrow host ranges, antigen
conservation may prevail, and this should
be considered in understanding their
pathogenesis and in devising methods
to prevent them.
EXPERIMENTAL PROCEDURES
Computational Analysis
Methods and associated references referring to
the genetic diversity analysis, HLA allele selection,
epitope predictions, and statistical analysis are
available in the Supplemental Experimental
Procedures.
Subject Recruitment and Patient
Information
The subjects studied were recruited and studied at
the MRC Unit, Gambia. They were HIV-seronega-
tive adults with newly diagnosed pulmonary TB
who gave informed consent to a prospective study
reviewed and approved by the New York Univer-
sity Institutional Review Board and by the Gambia
Government/Medical Research Council (MRC)
Joint Ethics Committee. After written informedconsent, 30 ml of heparin-anticoagulated blood was obtained by venipuncture
for the diluted whole blood assay with individual epitope peptides as the anti-
genic stimuli (Black et al., 2001, 2009).
Human T Cell Responses to Candidate Epitope Peptides
Peptides were synthesized by EZ Biolabs and reconstituted in water or DMSO.
Stocks were diluted to 1 mg/ml and stored in aliquots. In a 96-well plate, each
peptidewas added to a final concentration of 10 mg/ml in an individual well con-
taining whole blood diluted with nine volumes of RPMI 1640. Samples without
stimuluswere usedas negative controls to allowcalculationof themagnitude of
the induced responses. Phytohemagglutinin (PHA; 5 mg/ml), purified protein
derivative (PPD; StatenSerum Institute, Denmark), andapool of 35 overlapping
15-mer peptides (2.5 mg/ml) derived from the 6 kDa Early Secreted Antigenic
Target and the Culture Filtrate Protein-10 protein (ESAT-6/CFP-10) were
used as positive controls (Tientcheu et al., 2014). Antigens were stimulated in
triplicate, and after 7 days of incubation at 37C in a humidified CO2 incubator,
supernatants were removed for assay of IFN-g.
ELISA of Whole Blood Stimulated Supernatants
Supernatants were analyzed for IFN-g by ELISA as previously described
(Black et al., 2009). In Table S7, the values shown represent the average of
duplicate wells for each antigen. The stimulation index (SI) was calculated
for each response by dividing the concentration of IFN-g in the stimulatedwells
by the unstimulated negative control for each subject. A positive response was
defined as a SIR 2.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and nine tables and can be found with this article online at http://dx.doi.org/
10.1016/j.chom.2015.10.008.
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